
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded nasal spray containing xylitol, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No FDA-approved (NDA or ANDA) product containing xylitol is listed. Products containing it are filed in the directory as unapproved drugs and homeopathic products, in spray and liquid forms.
This dose form is water-containing (aqueous). Under USP <795>, aqueous preparations carry shorter default beyond-use dates than nonaqueous ones, and a preservative in the base allows a longer date than no preservative. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Xylitol is a sugar alcohol sweetener, not an approved drug, that a pharmacy may use in preparations when a prescriber orders it.
Xylitol is a five-carbon sugar alcohol (polyol) about as sweet as table sugar, found naturally in some fruits and vegetables. FDA describes it as a lower-calorie sugar substitute used in sugar-free gum and candy, toothpaste, mouthwash, cough syrup, chewable vitamins and over-the-counter medicines. Federal food rules permit xylitol in foods for special dietary uses. It is not an FDA-approved drug: the few drug listings that name it as an active ingredient are marketed as unapproved or homeopathic products. Proposed benefits include replacing sugar to lower tooth decay risk and possible effects against the cavity bacterium Streptococcus mutans. A prescriber might order a preparation containing xylitol, for example as a sweetener or in an oral care product. Compounded preparations are not FDA-approved and require a prescription.
Xylitol has no FDA drug label and no boxed warning. Large amounts can cause bloating and loose stools because unabsorbed xylitol draws water into the gut. NIH reports that higher blood xylitol levels were linked to more heart attacks and strokes in a large observational study, and that xylitol made platelets more prone to clotting; this does not prove it causes these events, and the researchers did not advise people to stop using it. No drug interactions were found in the sources used. No LactMed record or pregnancy data for xylitol were found; if you are pregnant or breastfeeding, talk to your prescriber or pharmacist before use. FDA warns xylitol is dangerous for dogs: it can cause a rapid, severe drop in blood sugar with vomiting, weakness, collapse or seizures, so keep xylitol products away from pets. Talk to your prescriber or pharmacist about side effects.
Xylitol is a polyol with a very low glycemic index and does not raise blood glucose or insulin, per a 2019 review in Nutrients. About half of an oral dose is absorbed in the small intestine by passive diffusion; the absorbed fraction is metabolized mainly in the liver through the pentose phosphate pathway, while the remainder is fermented in the colon. Osmotic effects of unabsorbed xylitol account for laxation and bloating. Proposed anticaries mechanisms are sucrose replacement, stimulation of saliva flow and inhibition of Streptococcus mutans. A 2016 Cochrane review found moderate-quality evidence that xylitol given to healthy children attending daycare may reduce the risk of acute otitis media, with inconclusive results during respiratory infections or in otitis-prone children; this is not an FDA-approved indication. No labeled indications exist. 21 CFR 172.395 allows xylitol in foods for special dietary uses at the amount needed for its intended effect. A 2024 study reported prothrombotic platelet effects after a xylitol-sweetened drink and an association between plasma xylitol and major adverse cardiovascular events; causation is not established. In dogs, xylitol triggers insulin release and hypoglycemia; FDA notes it does not stimulate insulin release in people. Dosing is per prescriber. Monitor GI tolerance.
Wash your hands and blow your nose gently. Prime the pump if your label says to. Keep your head upright, close one nostril with a finger, insert the tip into the other nostril and breathe in slowly while pressing the pump the number of times on your label. Repeat in the other nostril if directed. Wipe the nozzle, recap, and wash your hands. Do not share the bottle.
Nasal sprays are aqueous. Under USP <795>, a preserved spray usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Follow the storage line on your label, keep out of reach of children, and discard after the beyond-use date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Inhale intranasally